What’s New? - Preliminary Data Demonstrates KIO-301 Restored Visual Function in Retinitis Pigmentosa Study.


We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclinical Phase One Phase Two Phase Three
Retinal Disease Programs
KIO-301 (Intravitreal) Retinitis Pigmentosa
Stargardt’s Disease
KIO-104 (Intravitreal) Posterior Non-Infectious Uveitis
Ancillary Anterior Segment Programs*
KIO-101 (Eyedrop) Ocular Presentation of Rheumatoid Arthritis +
KIO-201 (Eyedrop) Persistent Corneal Epithelial Defects
Corneal Surgical Wounds
KIO-301 received Orphan Drug Designation from the FDA – March 2022.
KIO-104 received Orphan Drug Designation (EU) – May 2015.
*Ancillary programs have demonstrated proof-of-concept and will be advanced through potential strategic collaborations, asset sales, or licensing agreements.

These therapeutics are still in development and are not yet approved for commercial use.

Loading RSS Feed